AU770157B2 - Use of semaphorin for modulation of cellular efflux - Google Patents

Use of semaphorin for modulation of cellular efflux Download PDF

Info

Publication number
AU770157B2
AU770157B2 AU73556/00A AU7355600A AU770157B2 AU 770157 B2 AU770157 B2 AU 770157B2 AU 73556/00 A AU73556/00 A AU 73556/00A AU 7355600 A AU7355600 A AU 7355600A AU 770157 B2 AU770157 B2 AU 770157B2
Authority
AU
Australia
Prior art keywords
leu
ser
lys
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73556/00A
Other languages
English (en)
Other versions
AU7355600A (en
Inventor
Melanie K Spriggs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU7355600A publication Critical patent/AU7355600A/en
Application granted granted Critical
Publication of AU770157B2 publication Critical patent/AU770157B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU73556/00A 1999-09-08 2000-09-07 Use of semaphorin for modulation of cellular efflux Ceased AU770157B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15291499P 1999-09-08 1999-09-08
US60/152914 1999-09-08
US15625799P 1999-09-27 1999-09-27
US60/156257 1999-09-27
US17390699P 1999-12-29 1999-12-29
US60/173906 1999-12-29
PCT/US2000/024560 WO2001018044A2 (en) 1999-09-08 2000-09-07 Use of semaphorin for modulation of cellular efflux

Publications (2)

Publication Number Publication Date
AU7355600A AU7355600A (en) 2001-04-10
AU770157B2 true AU770157B2 (en) 2004-02-12

Family

ID=27387351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73556/00A Ceased AU770157B2 (en) 1999-09-08 2000-09-07 Use of semaphorin for modulation of cellular efflux

Country Status (4)

Country Link
EP (1) EP1210368A2 (de)
AU (1) AU770157B2 (de)
CA (1) CA2384104A1 (de)
WO (1) WO2001018044A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
EP1429801A1 (de) * 2001-09-26 2004-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neuropilin als neuer therapeutischen zielpunkt zur modulation von immunantworten

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007701A1 (en) * 1993-09-17 1995-03-23 Romano Deghenghi Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
WO1999021997A1 (en) * 1997-10-28 1999-05-06 Immunex Corporation Viral encoded semaphorin protein receptor dna and polypeptides
AU2982799A (en) * 1998-03-03 1999-09-20 Zymogenetics Inc. Human semaphorin zsmf-7

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639856A (en) * 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007701A1 (en) * 1993-09-17 1995-03-23 Romano Deghenghi Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
WO1999021997A1 (en) * 1997-10-28 1999-05-06 Immunex Corporation Viral encoded semaphorin protein receptor dna and polypeptides
AU2982799A (en) * 1998-03-03 1999-09-20 Zymogenetics Inc. Human semaphorin zsmf-7

Also Published As

Publication number Publication date
EP1210368A2 (de) 2002-06-05
WO2001018044A3 (en) 2001-10-25
CA2384104A1 (en) 2001-03-15
WO2001018044A2 (en) 2001-03-15
AU7355600A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
Amarante-Mendes et al. Therapeutic applications of TRAIL receptor agonists in cancer and beyond
US8211864B2 (en) Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors
AU745235B2 (en) Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US20120178163A1 (en) Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
KR20030007899A (ko) 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
CA2911863A1 (en) Methods and compositions for the treatment of cancer
CN101389651A (zh) 受体特异性肿瘤坏死因子相关的细胞凋亡诱导配体(trail)的突变体
JP2001502538A (ja) ミニｅ１ａ遺伝子及び遺伝子産物
BG108020A (bg) Методи за лечение или профилактика на кожни заболявания с приложение на cd2-свързващи агенти
US6218363B1 (en) MHC peptides and methods of use
US6448078B1 (en) Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
Fischer et al. Cutting-edge apoptosis-based therapeutics: a panacea for cancer?
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
Li et al. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo
AU770157B2 (en) Use of semaphorin for modulation of cellular efflux
US6191269B1 (en) Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
JP2011102322A (ja) 毒性が低下したｔｎｆファミリーのリガンド、リガンドのアゴニストの投与方法
WO2001017559A9 (en) Semaphorin modulation of immune cell migration
US7176179B1 (en) Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
WO2001052883A1 (en) Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
WO2022056493A1 (en) Biomarker driven methods for treating major depressive disorder
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
JP2023524558A (ja) Ｐｃｎａ相互作用モチーフを含むペプチドの固形癌の治療における使用
AU767967B2 (en) Modulators of TNF receptor associated factor (TRAF), their preparation and use
Ezhevsky et al. Protein transduction strategies for target and mechanism validation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)